K. Larsen

发表

Vortioxetine reduces BOLD signal during performance of the N-back working memory task: a randomised neuroimaging trial in remitted depressed patients and healthy controls

G. Dawson, J. Deakin, C. Harmer, 2017, Molecular Psychiatry.

Alcohol withdrawal syndrome: symptom-triggered versus fixed-schedule treatment in an outpatient setting.

K. Larsen, U. Becker, N. Hornnes, 2011, Alcohol and alcoholism.

The cardiovascular safety profile of escitalopram

M. Thase, S. Kennedy, K. Larsen, 2013, European Neuropsychopharmacology.

Patient-reported depression severity and cognitive symptoms as determinants of functioning in patients with major depressive disorder: a secondary analysis of the 2-year prospective PERFORM study

J. Haro, K. Larsen, D. Saragoussi, 2019, Neuropsychiatric disease and treatment.

A Network Meta-Analysis Comparing Effects of Various Antidepressant Classes on the Digit Symbol Substitution Test (DSST) as a Measure of Cognitive Dysfunction in Patients with Major Depressive Disorder

B. Baune, K. Larsen, M. Brignone, 2017, The international journal of neuropsychopharmacology.

Patient Response Trajectories in Major Depressive Disorder.

M. Thase, S. Kennedy, K. Larsen, 2020, Psychopharmacology bulletin.

Assessment of patient life engagement in major depressive disorder using items from the Inventory of Depressive Symptomatology Self-Report (IDS-SR).

M. Thase, R. McIntyre, K. Larsen, 2023, Journal of psychiatric research.

A New Principal Stratum Estimand Investigating the Treatment Effect in Patients Who Would Comply, If Treated With a Specific Treatment

K. Larsen, M. K. Josiassen, 2020 .

Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo

D. Baldwin, K. Larsen, Satoshi Asakura, 2016, European Neuropsychopharmacology.

Effects of adjunctive brexpiprazole on patient life engagement in major depressive disorder: Post hoc analysis of Inventory of Depressive Symptomatology Self-Report data.

M. Thase, R. McIntyre, K. Larsen, 2023, Journal of psychiatric research.

Specific antismoking advice after stroke.

G. Boysen, K. Larsen, N. Hornnes, 2014, Danish medical journal.

A psychometric validation of the Short Alcohol Withdrawal Scale (SAWS).

K. Larsen, U. Becker, N. Hornnes, 2010, Alcohol and alcoholism.

Assessing the ‘true’ effect of active antidepressant therapy v. placebo in major depressive disorder: use of a mixture model

M. Thase, S. Kennedy, K. Larsen, 2011, British Journal of Psychiatry.

placebo in major depressive disorder: use of a mixture model v. Assessing the 'true' effect of active antidepressant therapy

M. Thase, S. Kennedy, K. Larsen, 2011 .

Combining escitalopram with gaboxadol provides no additional benefit in the treatment of patients with severe major depressive disorder.

S. Kasper, K. Larsen, B. Ebert, 2012, The international journal of neuropsychopharmacology.

P.2.d.012 Combining escitalopram with gaboxadol provides no additional benefit in the treatment of patients with severe major depressive disorder

S. Kasper, K. Larsen, B. Ebert, 2011, European Neuropsychopharmacology.

Testing anxious depression as a predictor and moderator of symptom improvement in major depressive disorder during treatment with escitalopram

K. Larsen, G. Papakostas, 2011, European Archives of Psychiatry and Clinical Neuroscience.

Blood pressure 1 year after stroke: the need to optimize secondary prevention.

G. Boysen, K. Larsen, N. Hornnes, 2011, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

Rejoinder to Letter to the Editor on “A New Principal Stratum Estimand Investigating the Treatment Effect in Patients Who Would Comply, If Treated With a Specific Treatment”

K. Larsen, M. K. Josiassen, 2021, Statistics in Biopharmaceutical Research.

Little Change of Modifiable Risk Factors 1 Year after Stroke: a Pilot Study

G. Boysen, K. Larsen, N. Hornnes, 2010, International journal of stroke : official journal of the International Stroke Society.